WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H531007
CAS#: 603-50-9
Description: Bisacodyl, also known as Dulcolax, is a stimulant laxative drug. Oral bisacodyl is an effective and well-tolerated treatment for patients with chronic constipation. It improves bowel function, constipation-related symptoms, and disease-related quality of life.
Hodoodo Cat#: H531007
Name: Bisacodyl
CAS#: 603-50-9
Chemical Formula: C22H19NO4
Exact Mass: 361.13
Molecular Weight: 361.397
Elemental Analysis: C, 73.12; H, 5.30; N, 3.88; O, 17.71
Synonym: Bisacodyl, Durolax, Dulcolax, Fenilaxan, Neolax, Ulcolax
IUPAC/Chemical Name: (pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate
InChi Key: KHOITXIGCFIULA-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H19NO4/c1-15(24)26-19-10-6-17(7-11-19)22(21-5-3-4-14-23-21)18-8-12-20(13-9-18)27-16(2)25/h3-14,22H,1-2H3
SMILES Code: CC(OC1=CC=C(C(C2=CC=C(OC(C)=O)C=C2)C3=NC=CC=C3)C=C1)=O
Appearance: White to off-white crystalline powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Bisacodyl is a stimulant laxative agent that works directly on the colon to produce a bowel movement. |
| In vitro activity: | Bisacodyl (0.1–1 µM) concentration-dependently suppressed TGF-α-induced MUC5AC production (Fig. 1B). In the presence of TGF-α alone, MUC5AC in the culture medium was detected at 12 h, and its levels increased time-dependently. Bisacodyl significantly suppressed the increased secretion of MUC5AC at all observation points (Fig. 1C). Reference: Biol Pharm Bull. 2021;44(4):590-592. https://pubmed.ncbi.nlm.nih.gov/33790109/ |
| In vivo activity: | After one month of bisacodyl treatment, there were significant differences in the number of defecations, dry weight of feces, and intestinal transit time among the control rat group, STC group, and STC bisacodyl group (P=0.000). The number of defecations in the STC bisacodyl group was greater than that of the STC group (P<0.05), while dry weight of feces and intestinal transit time in the STC bisacodyl group were less than in the STC group (P<0.05) (Table 2). Reference: Braz J Med Biol Res. 2018; 51(7): e7372. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995042/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 41.0 | 113.45 | |
| DMF | 30.0 | 83.01 | |
| DMF:PBS (pH 7.2) (1:7) | 0.1 | 0.33 | |
| Water | 0.1 | 0.28 |
The following data is based on the product molecular weight 361.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Ishibashi J, Isohama Y. Bisacodyl Suppresses TGF-α-Induced MUC5AC Production in NCI-H292 Cells. Biol Pharm Bull. 2021;44(4):590-592. doi: 10.1248/bpb.b20-00886. PMID: 33790109. 2. Min YW, Ko EJ, Kim JH, Lee JY, Kim HC, Lee WY, Rhee PL. Increased Tone of the Human Colon Muscle by Bisacodyl In Vitro. J Neurogastroenterol Motil. 2018 Apr 30;24(2):317-323. doi: 10.5056/jnm17063. PMID: 29605986; PMCID: PMC5885731. 3. Wang YB, Ling J, Zhang WZ, Li G, Qiu W, Zheng JH, Zhao XH. Effect of bisacodyl on rats with slow transit constipation. Braz J Med Biol Res. 2018;51(7):e7372. doi: 10.1590/1414-431x20187372. Epub 2018 May 28. PMID: 29846410; PMCID: PMC5995042. |
| In vitro protocol: | 1. Ishibashi J, Isohama Y. Bisacodyl Suppresses TGF-α-Induced MUC5AC Production in NCI-H292 Cells. Biol Pharm Bull. 2021;44(4):590-592. doi: 10.1248/bpb.b20-00886. PMID: 33790109. 2. Min YW, Ko EJ, Kim JH, Lee JY, Kim HC, Lee WY, Rhee PL. Increased Tone of the Human Colon Muscle by Bisacodyl In Vitro. J Neurogastroenterol Motil. 2018 Apr 30;24(2):317-323. doi: 10.5056/jnm17063. PMID: 29605986; PMCID: PMC5885731. |
| In vivo protocol: | 1. Wang YB, Ling J, Zhang WZ, Li G, Qiu W, Zheng JH, Zhao XH. Effect of bisacodyl on rats with slow transit constipation. Braz J Med Biol Res. 2018;51(7):e7372. doi: 10.1590/1414-431x20187372. Epub 2018 May 28. PMID: 29846410; PMCID: PMC5995042. |
1: Bang KB, Jeong EH, Jeong WS, Chae HB, Kim NH, Lee TH, Kim JY, Jung YS, Park JH, Sohn CI, Choi KY, Park DI. [Efficacy of bisacodyl given as part of a polyethylene glycol-based bowel preparation prior to colonoscopy in hospitalized patients: a prospective ramdomized trial]. Korean J Gastroenterol. 2014 Nov;64(5):268-77. Korean. PubMed PMID: 25420736.
2: Parente F, Vailati C, Bargiggia S, Manes G, Fontana P, Masci E, Arena M, Spinzi G, Baccarin A, Mazzoleni G, Testoni PA. 2-Litre polyethylene glycol-citrate-simethicone plus bisacodyl versus 4-litre polyethylene glycol as preparation for colonoscopy in chronic constipation. Dig Liver Dis. 2015 Oct;47(10):857-63. doi: 10.1016/j.dld.2015.06.008. Epub 2015 Jul 6. PubMed PMID: 26232311.
3: Kamm MA, Mueller-Lissner S, Wald A, Richter E, Swallow R, Gessner U. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol. 2011 Jul;9(7):577-83. doi: 10.1016/j.cgh.2011.03.026. Epub 2011 Mar 25. PubMed PMID: 21440672.
4: Amouzeshi A, Amouzeshi Z, Naseh G, Vejdan SA, Tanha AS, Hosseinzadeh M, Vagharseyyedin SR. The comparison of saline enema and bisacodyl in rectal preparation before anorectal surgery. J Surg Res. 2015 Dec;199(2):322-5. doi: 10.1016/j.jss.2015.04.029. Epub 2015 Apr 15. PubMed PMID: 25979561.
5: Li S, Wang L, Jiang J, Tang P, Wang Q, Wu D, Li H. Investigations of bisacodyl with modified β-cyclodextrins: Characterization, molecular modeling, and effect of PEG. Carbohydr Polym. 2015 Dec 10;134:82-91. doi: 10.1016/j.carbpol.2015.07.074. Epub 2015 Jul 26. PubMed PMID: 26428103.
6: Tae CH, Jung SA, Na SK, Song HK, Moon CM, Kim SE, Shim KN, Jung HK, Moon IH. The use of low-volume polyethylene glycol containing ascorbic acid versus 2 L of polyethylene glycol plus bisacodyl as bowel preparation for colonoscopy. Scand J Gastroenterol. 2015 Aug;50(8):1039-44. doi: 10.3109/00365521.2014.1000961. Epub 2015 Apr 10. PubMed PMID: 25862428.
7: Chen ZY, Shen HS, Luo MY, Duan CJ, Cai WL, Lu HB, Zhang GP, Liu Y, Liang JZ. Pilot study on efficacy of reduced cathartic bowel preparation with polyethylene glycol and bisacodyl. World J Gastroenterol. 2013 Jan 28;19(4):561-8. doi: 10.3748/wjg.v19.i4.561. PubMed PMID: 23382637; PubMed Central PMCID: PMC3558582.
8: Clark RE, Godfrey JD, Choudhary A, Ashraf I, Matteson ML, Bechtold ML. Low-volume polyethylene glycol and bisacodyl for bowel preparation prior to colonoscopy: a meta-analysis. Ann Gastroenterol. 2013;26(4):319-324. Review. PubMed PMID: 24714413; PubMed Central PMCID: PMC3959486.
9: Yi Z, Jie C, Wenyi Z, Bin X, Hongzhu J. Comparison of efficacies of vegetable oil based and polyethylene glycol based bisacodyl suppositories in treating patients with neurogenic bowel dysfunction after spinal cord injury: a meta-analysis. Turk J Gastroenterol. 2014 Oct;25(5):488-92. doi: 10.5152/tjg.2014.6708. Review. PubMed PMID: 25417608.
10: Soufi-Afshar I, Moghadamnia A, Bijani A, Kazemi S, Shokri-Shirvani J. Comparison of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation. Caspian J Intern Med. 2016 Winter;7(1):19-24. PubMed PMID: 26958328; PubMed Central PMCID: PMC4761118.
11: Yenidogan E, Okan I, Kayaoglu HA, Akgul GG, Sansal M, Tali S, Ozsoy Z, Sahin M. Same-day colonoscopy preparation with Senna alkaloids and bisacodyl tablets: a pilot study. World J Gastroenterol. 2014 Nov 7;20(41):15382-6. doi: 10.3748/wjg.v20.i41.15382. PubMed PMID: 25386088; PubMed Central PMCID: PMC4223273.
12: Ling J, Zhang W, Xu B, Qiu W, Wang Y. [Experimental study of Bisacodyl in the treatment of slow transit constipation model rats]. Zhonghua Wei Chang Wai Ke Za Zhi. 2016 Dec 25;19(12):1365-1369. Chinese. PubMed PMID: 28000192.
13: Kim JW, Han JH, Boo SJ, Ko OB, Park SK, Park SH, Yang DH, Jung KW, Kim KJ, Ye BD, Myung SJ, Yang SK, Kim JH, Byeon JS. Rescue bowel preparation: same day 2 L polyethylene glycol addition, not superior to bisacodyl addition 7 days later. Dig Dis Sci. 2014 Sep;59(9):2215-21. doi: 10.1007/s10620-014-3125-3. Epub 2014 Apr 20. PubMed PMID: 24748228.
14: Fujita T, Karaki S, Tateoka T, Kuwahara A. Desacetyl bisacodyl-induced epithelial Cl(-) secretion in rat colon and rectum. Biomed Res. 2016;37(1):13-20. doi: 10.2220/biomedres.37.13. PubMed PMID: 26912136.
15: Kang SH, Jeen YT, Lee JH, Yoo IK, Lee JM, Kim SH, Choi HS, Kim ES, Keum B, Lee HS, Chun HJ, Kim CD. Comparison of a split-dose bowel preparation with 2 liters of polyethylene glycol plus ascorbic acid and 1 liter of polyethylene glycol plus ascorbic acid and bisacodyl before colonoscopy. Gastrointest Endosc. 2016 Nov 23. pii: S0016-5107(16)30762-3. doi: 10.1016/j.gie.2016.10.040. [Epub ahead of print] PubMed PMID: 27889546.
16: Valiante F, Bellumat A, De Bona M, De Boni M. Bisacodyl plus split 2-L polyethylene glycol-citrate-simethicone improves quality of bowel preparation before screening colonoscopy. World J Gastroenterol. 2013 Sep 7;19(33):5493-9. doi: 10.3748/wjg.v19.i33.5493. PubMed PMID: 24023492; PubMed Central PMCID: PMC3761102.
17: Ikarashi N, Baba K, Ushiki T, Kon R, Mimura A, Toda T, Ishii M, Ochiai W, Sugiyama K. The laxative effect of bisacodyl is attributable to decreased aquaporin-3 expression in the colon induced by increased PGE2 secretion from macrophages. Am J Physiol Gastrointest Liver Physiol. 2011 Nov;301(5):G887-95. doi: 10.1152/ajpgi.00286.2011. Epub 2011 Aug 25. PubMed PMID: 21868635.
18: Zeniou M, Fève M, Mameri S, Dong J, Salomé C, Chen W, El-Habr EA, Bousson F, Sy M, Obszynski J, Boh A, Villa P, Assad Kahn S, Didier B, Bagnard D, Junier MP, Chneiweiss H, Haiech J, Hibert M, Kilhoffer MC. Chemical Library Screening and Structure-Function Relationship Studies Identify Bisacodyl as a Potent and Selective Cytotoxic Agent Towards Quiescent Human Glioblastoma Tumor Stem-Like Cells. PLoS One. 2015 Aug 13;10(8):e0134793. doi: 10.1371/journal.pone.0134793. eCollection 2015. PubMed PMID: 26270679; PubMed Central PMCID: PMC4536076.
19: Manes G, Fontana P, de Nucci G, Radaelli F, Hassan C, Ardizzone S. Colon Cleansing for Colonoscopy in Patients with Ulcerative Colitis: Efficacy and Acceptability of a 2-L PEG Plus Bisacodyl Versus 4-L PEG. Inflamm Bowel Dis. 2015 Sep;21(9):2137-44. doi: 10.1097/MIB.0000000000000463. PubMed PMID: 26164666.
20: Cesaro P, Hassan C, Spada C, Petruzziello L, Vitale G, Costamagna G. A new low-volume isosmotic polyethylene glycol solution plus bisacodyl versus split-dose 4 L polyethylene glycol for bowel cleansing prior to colonoscopy: a randomised controlled trial. Dig Liver Dis. 2013 Jan;45(1):23-7. doi: 10.1016/j.dld.2012.07.011. Epub 2012 Aug 21. PubMed PMID: 22917636.
